Protagonist Therapeutics PTGX

Drug Manufacturers - General, Healthcare

$138.43

−0.79%

Market cap: $9B
PE: 134×; 2y median 58.3×
Forward PE: n/m; not a meaningful number
Price to sales: 31.8×
EV/EBIT: 140×
Revenue, 12 months: $282M; +35% on a year ago
Net margin: 29.4%
Free cash flow yield: 1.5%

Protagonist Therapeutics trades at 134× trailing earnings, pricier than 81% of the last ten years. Revenue was $282M over the last twelve months, up 35% on a year earlier with a 29% net margin.

Charts

Financials

Income statement for PTGX, by quarter
Income statement	Q3 FY23	Q4 FY23	Q1 FY24	Q2 FY24	Q3 FY24	Q4 FY24	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
	$0	$60M	$255M	$4.2M	$4.7M	$170.6M+184%	$28.3M−89%	$5.5M+33%	$4.7M+1%	$7.4M−96%	$56.4M+99%	$213.5M+3749%
R&D	$30.7M+21%	$28.9M−3%	$33.7M+23%	$33.5M+1%	$36M+17%	$34.9M+21%	$35.9M+6%	$37M+11%	$40M+11%	$46.4M+33%	$46.7M+30%	$42.1M+14%
SG&A	$7.7M+11%	$8.1M+21%	$14.9M+73%	$9.4M+3%	$10.2M+33%	$9M+11%	$11.7M−21%	$10.6M+12%	$11.1M+10%	$11.4M+28%	$13.3M+13%	$12.6M+20%
	−$38.3M+19%	$23M	$206.3M	−$38.8M−8%	−$41.5M+8%	$126.8M+450%	−$19.3M	−$42M+8%	−$46.4M+12%	−$50.4M	−$3.6M−81%	$158.8M
Interest expense	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Pre-tax income	−$34.1M	$27.3M	$210.7M	−$31.3M−19%	−$33.6M−1%	$133.7M+389%	−$11.7M	−$34.6M+11%	−$39.3M+17%	−$43.7M	$2.3M	$165.1M
	$0	n/a	$3.3M	−$676K	−$420K	$2M	$0	$172K	$0	$666K−67%	−$1.5M	$2.3M+1217%
Net income	−$34.1M+9%	$27.3M	$207.3M	−$30.6M−20%	−$33.2M−3%	$131.7M+382%	−$11.7M	−$34.8M+14%	−$39.3M+19%	−$44.4M	$3.8M	$162.8M
	−$0.58−9%	$0.45	$3.26	−$0.50−27%	−$0.54−7%	$1.98+340%	−$0.19	−$0.55+10%	−$0.62+15%	−$0.69	$0.05	$2.29
	59.2M+21%	60.4M+23%	63.6M+26%	61.3M+8%	61.8M+4%	66.5M+10%	63M−1%	63.5M+4%	63.8M+3%	64M−4%	70.5M+12%	71M+12%

R&D: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.

SG&A: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.

Operating income: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.

Net income: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.

EPS, diluted: 9 periods, Q1 FY15 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: Q1 FY15 and Q1 FY16: share-days: the 6-month average less the second quarter's. 9 periods, Q4 FY15 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY23 and Q4 FY24: share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest Protagonist Therapeutics' size, closest first.

Company	Market cap	PE	Its 10y median PE	P/S	Revenue growth	Net margin
PTGXProtagonist Therapeutics	$9B	134×	58.3×	31.8×	+35%	29.4%
CORTCorcept Therapeutics	$9.3B	204×	28.3×	11.2×	+16%	6.6%
TGTXTG Therapeutics	$8.3B	19.8×	19.4×	10.4×	+76%	55.2%
BMRNBiomarin Pharmaceutical	$10.8B	151×	70.6×	3.2×	+11%	2.1%
ALKSAlkermes plc.	$7.3B	115×	16.0×	4.4×	+11%	4.0%
AMRXAmneal Pharmaceuticals	$6.5B	41.6×	51.5×	2.1×	+9%	5.0%
LGNDLigand Pharmaceuticals	$6.1B	32.3×	37.7×	20.8×	+55%	67.9%
KNSAKiniksa Pharmaceuticals International	$6B	79.1×	85.3×	7.1×	+59%	9.6%
JAZZJazz Pharmaceuticals	$13.9B	14.6×	20.2×	3.0×	+13%	20.4%
INDVIndivior Pharmaceuticals	$4.1B	12.4×	20.1×	3.1×	+13%	26.7%
ARQTArcutis Biotherapeutics	$3.9B	142×	115×	8.5×	+76%	6.1%
Peer median	$6.9B	60.3×	33.0×	5.8×	+15%	8.1%